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Background: To compare the quantitative antibiotic use between hospitals or hospital units and to
explore differences, adjustment for severity of illness of hospitalized patients is essential. The case
mix index (CMI) is an economic surrogate marker (i.e. the total cost weights of all inpatients per a
defined time period divided by the number of admissions) to describe the average patients’ morbidity
of individual hospitals. We aimed to investigate the correlation between CMI and hospital antibiotic
use.
Methods: We used weighted linear regression analysis to evaluate the correlation between in-hospital
antibiotic use in 2006 and CMI of 18 departments of the tertiary care University Hospital Zurich and of
10 primary and 2 secondary acute care hospitals in the Canton of Zurich in Switzerland.
Results: Antibiotic use varied substantially between different departments of the university hospital
[defined daily doses (DDD)/100 bed-days, 68.04; range, 20.97–323.37] and between primary and
secondary care hospitals (range of DDD/100 bed-days, 15.45–57.05). Antibiotic use of university
hospital departments and the different hospitals, respectively, correlated with CMI when calculated in
DDD/100 bed-days [coefficient of determination (R2), 0.57 (P 5 0.0002) and 0.46 (P5 0.0065)], as well as
when calculated in DDD/100 admissions [R2, 0.48 (P5 0.0008) and 0.85 (P < 0.0001), respectively].
Conclusions: Antibiotic use correlated with CMI across various specialties of a university hospital and
across different acute care hospitals. For benchmarking antibiotic use within and across hospitals,
adjustment for CMI may be a useful tool in order to take into account the differences in hospital
category and patients’ morbidities.
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Introduction
Increased and inappropriate antibiotic use among outpatients and
in hospitals has been noted worldwide,1 – 4 and the association
between antibiotic use and the emergence of antibiotic resistance
is well established.5 – 7 Antibiotic stewardship programmes in
hospitals are considered a major tool to address these problems.8
The quantitative and qualitative assessment of antibiotic use is
crucial to develop antibiotic policies and is the mainstay of anti-
biotic stewardship programmes. The amount of antibiotic use
has been found to vary widely across countries in the ambulat-
ory as well as in the hospital setting.9,10 Reasons for these
variations may include different antibiotic policies, physicians’
education, culture-dependent patients’ expectations, varying anti-
bacterial resistance rates and differences in measuring antibiotic
use. The ATC/DDD system promoted by the World Health
Organization is the standard method for reporting antibiotic use.11
However, different formats for measuring and reporting antibiotic
use are still applied in the current literature.1,4,12,13
Clinicians often justify high antibiotic use in their particular
setting with differences in patients’ morbidities. Several scores
are used to classify patients’ severity of illness based on their
co-morbidities in clinical studies,14,15 but, unfortunately, there
is no straightforward tool to routinely obtain morbidity scores
for all inpatients of an entire hospital. Using hospital economic
data might be an approach to systematically account for
co-morbidities. The case mix index (CMI) is such an economic
parameter that is calculated using diagnosis-related groups
(DRGs), a measure that is nowadays routinely obtained in
various countries as a basis for hospital reimbursement.16
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DRGs, developed as an instrument to relate the case mix of a
hospital to the costs, classify patients depending on their diagno-
sis, treatments, age and other information into mutually exclu-
sive, clinically and financially homogeneous categories. This is
done by collecting information about a patient’s medical needs
and subsequently converting this information into codes. These
codes describe patients’ conditions, their severity of illness and
their prognoses.17 DRGs were first developed in the 1960s at Yale
University.16,18 Since then, DRGs or similar grouping systems
have been installed by most European countries. Most classifi-
cation methods are based, to some extent, on the HealthCare
Financing Administration system that was introduced in 1983
under the US Medicare system. Despite this similarity, there
are considerable differences in the methods for collecting cost
data and reimbursement rates among different countries.16,19
Nevertheless, DRGs are a useful and simple tool for defining and
measuring a hospital’s case mix complexity.
Associations between CMI and antibiotic use have been
studied in long-term care settings,20,21 but neither in large uni-
versity hospitals with a wide variation of antibiotic use and
CMIs across different departments, nor across various acute care
hospitals. We therefore aimed to evaluate the correlation
between antibiotic use and CMI in these two settings.
Methods
Study design
We performed a retrospective observational study of antibiotic use
and CMI in different departments of the University Hospital, Zurich
and in another 12 acute care hospitals in the Canton of Zurich, a
state in Switzerland, during the study period between 1 January
2006 and 31 December 2006.
Case mix index
The CMI equals the sum of the total cost weights of all inpatients
per a defined time period divided by the number of admissions. The
‘cost weight’ of a DRG X is defined by dividing the average cost
per case of DRG X by the mean cost per case on a nationwide level.
In this way, each DRG is allocated a cost weight. In Switzerland,
cost weights are regularly recalculated and recorded in the database
of APDRG Swiss.22
Setting
The University Hospital Zurich is an 861 bed tertiary care teaching
hospital. It covers all specialties except paediatrics and orthopaedics.
The psychiatry ward was excluded from the analysis since cost
weights for psychiatric patients have not yet been defined in
Switzerland. About 1959 healthy newborns were cared for in the
obstetrics department. In addition, the same department included a
23 bed neonatology ward. Six intensive care units (ICUs), including
a burn unit, with a total of 59 beds are assigned to different depart-
ments. Bone marrow transplantations are performed in a specialized
unit. In 2006, a total of 33 663 patients was admitted accounting for
243 235 bed-days (day of admission and day of discharge counted
together as 1 bed-day).23 The mean length of stay (LOS) in the
wards, the ICUs and the bone marrow transplantation unit was 4.6
(range, 3.0–11.5), 3.7 (range, 3.1–5.8) and 20.8 days, respectively.
The other 12 hospitals of the Canton of Zurich included 10
primary and 2 secondary care hospitals. In 2006, the numbers of
beds of these hospitals ranged from 92 to 554, the number of inten-
sive care beds from 4 to 16, the numbers of bed-days (day of admis-
sion and day of discharge counted together as 1 bed-day) from
22 521 to 152 674, the number of patients admitted from 3705 to
21 229 and the mean LOS from 4.3 to 18.4 days. An obstetrics
department was part of all but one of the hospitals with numbers of
newborns ranging from 321 to 1463. Paediatric wards were part of
one primary care hospital and both secondary care hospitals. Two
primary care hospitals included a long-term care unit, and one a
psychiatry ward. None of the hospitals had a rehabilitation ward.23
Most of the 13 hospitals had internal guidelines for antibiotic use.
Data collection
For the University Hospital Zurich, aggregate in-hospital antibiotic
use data, including deliveries and returns, were collected from the
hospital pharmacy and entered into a Microsoftw Office Access
2003 database, similar to ABC Calc developed by the Danish
Statens Serum Institut.24 Bed-days and numbers of admissions were
calculated from computerized hospital administration records of
each patient hospitalized for 24 h in the same hospital unit, count-
ing the days of admission and discharge together as one bed-day.
Defined daily doses (DDD)/100 bed-days and DDD/100 admissions
were calculated for each hospital department. The 2007 version
[Group ‘J01 (Antibacterials for systemic use)’] of the ATC Index
with DDDs was used.11
CMIs for patients hospitalized in these defined patient care areas
were calculated for the study year, using data provided by the
Division of Medical Coding Statistics of the University Hospital
Zurich based on cost weights for each patient. Version 1.6 of the
APDRG Grouper and Version 5.1 of the Swiss APDRG cost
weights were used.22 Diagnoses were coded with the ICD-10 WHO
Version 1.3, and treatments were coded with CHOP Version 8.0, a
Swiss translation of ICD-9-CM 2005. Cost weights of patients who
were transferred between hospital departments were counted for the
calculation of CMI of each location, accordingly.
For the other 12 hospitals of the Canton of Zurich, numbers of
bed-days, admissions and CMIs are published on a yearly basis by
the healthcare authorities of the Canton of Zurich.23 Cumulative
antibiotic use data for the year 2006 were obtained from the hospital
pharmacy of each hospital. Calculations of antibiotic use data were
carried out in analogy to the methods described earlier. The ana-
lyses were limited to somatic acute care units of the hospitals
(excluding long-term care units), except for one hospital where a
psychiatry ward and a long-term care unit could not be excluded
due to local pharmacy data management reasons.
Statistical analysis
We used Stata (Version 9.2, StataCorp, College Station, TX, USA)
for statistical analyses. Weighted linear regression analyses were
performed to determine the correlation between antibiotic use and
CMI. We used analytic weights according to the number of
bed-days of each department or hospital to reduce variation induced
by measures derived from smaller hospitals or departments. A
P value ,0.05 was considered statistically significant.
Results
Antibiotic use
Antibiotic use data are depicted in Figure 1, and data on LOS
in different hospitals are listed in the figure legend. At the
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university hospital, overall antibiotic use was 68.04 DDD/100
bed-days and 491.62 DDD/100 admissions, respectively. The
DDD/100 bed-days in the ICUs ranged from 101.31 to 176.23
and in the wards from 20.97 to 112.18. The highest antibiotic
use with 323.37 DDD/100 bed-days was recorded in the bone
marrow transplantation unit (Figure 1a).
In primary care hospitals, antibiotic use ranged from 15.45
to 57.05 DDD/100 bed-days and from 182.95 to 405.21 DDD/
100 admissions (Figure 1b). The corresponding numbers
for the two secondary care hospitals were 39.46 and 50.56
DDD/100 bed-days and 268.59 and 383.77 DDD/100 admis-
sions, respectively.
Correlation between antibiotic use and CMI
at the University Hospital
The CMI of the various units and departments described earlier
ranged from 3.57 to 6.45 in the ICUs and from 1.01 to 3.02 on
general wards. A CMI of 9.83 was calculated for the bone marrow
transplantation unit. The correlation between antibiotic use and
CMI is depicted in Figure 2. We found a significant correlation
between CMI and antibiotic use when calculated in DDD/100
bed-days [R2 ¼ 0.57, P ¼ 0.0002, slope ¼ 27.90 DDD/100
bed-days per CMI (95% CI 15.71–40.08)] as well as in the DDD/
100 admissions format [R2 ¼ 0.48, P ¼ 0.0008, slope ¼ 383.61
DDD/100 admissions per CMI (95% CI 186.18–581.05)].1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
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Figure 1. Antibiotic use. (a) Units of university hospital: 1, bone marrow
transplantation unit (LOS ¼ 20.8 days). 2–7, ICUs ordered by increasing
mean LOS: 2, neurosurgical ICU (LOS, 3.1 days); 3, cardiac surgery ICU
(LOS, 3.5 days); 4, medical ICU (LOS, 3.6 days); 5, general, thoracic and
transplant surgery ICU (LOS, 4.2 days); 6, trauma ICU (LOS, 4.3 days); 7,
burn ICU (LOS, 5.8 days); 8–18, different wards of departments, ordered
by increasing mean LOS: 8, ophthalmology/ear–nose–throat (LOS, 3.0
days); 9, urology (LOS, 3.6 days); 10, gynaecology and obstetrics (LOS,
4.1 days); 11, surgery (cardiac, thoracic, visceral, trauma and reconstructive
surgery) (LOS, 4.3 days); 12, neurosurgery (LOS, 4.3 days); 13, neurology
(LOS, 4.8 days); 14, internal medicine (LOS, 5.3 days); 15,
interdisciplinary private wards (LOS, 5.3 days); 16, dermatology (LOS, 6.9
days); 17, radiation therapy (LOS, 7.8 days); 18, rheumatology (LOS, 11.5
days). (b) All hospitals: 1–10, primary care hospitals, ordered by
increasing mean LOS. LOS of different hospitals are 4.3, 5.8, 5.8, 5.8, 6.0,
6.3, 6.3, 6.6, 10.4 and 18.4 days, respectively. 11 and 12, secondary care
hospitals, ordered by increasing mean LOS. LOSs of different hospitals are
6.8 and 7.6 days, respectively. 13, tertiary care university hospital (LOS,
7.2 days).
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Figure 2. Correlation between antibiotic use and CMI in a tertiary care
university hospital. Correlation between antibiotic use and CMI in different
wards of the University Hospital Zurich in 2006 measured in DDD/100
bed-days (upper panel) and DDD/100 admissions (lower panel). Weighted
linear regression was used with the size of the dots corresponding to the
number of bed-days. DDD, defined daily doses. ‘Antibiotics’ are all
substances of ATC group ‘J01 (Antibacterials for systemic use)’.
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Correlation of antibiotic use and CMI at the 13 hospitals
of the Canton of Zurich
The CMI of the 10 primary, the 2 secondary care hospitals and
the tertiary care University Hospital ranged from 0.7853 to
1.3624. Correlations between antibiotic use and CMI across
various hospitals of the greater Zurich area are displayed in
Figure 3. There was a significant correlation between CMI
and antibiotic use presented in the DDD/100 bed-days format
[R2 ¼ 0.46, P ¼ 0.0065, slope ¼ 47.96 DDD/100 bed-days per
CMI (95% CI 16.46–79.47)] as well as in the DDD/100 admis-
sions format [R2 ¼ 0.85, P, 0.0001, slope ¼ 403.25 DDD/100
admissions per CMI (95% CI 295.00–511.51)].
Discussion
The direct comparison of the quantity of antibiotic use between
hospitals or hospital units is flawed due to differences in the
average severity of illness of patients hospitalized in specific
institutions as well as due to different structures and missions of
hospitals. There is no defined benchmark for antibiotic use for
specific categories of hospitals (e.g. primary, secondary or ter-
tiary care). The CMI is an economic surrogate marker used to
describe the average morbidity of patients in hospitals. We
found a moderate correlation between antibiotic use and CMI
when analysing data of different departments and units of a
tertiary care university hospital, as well as when comparing
another 12 primary and secondary acute care hospitals in the
Canton of Zurich, a state in Northern Switzerland. Such corre-
lations were found when antibiotic use was calculated both in
DDD/100 bed-days and in DDD/100 admissions. Consequently,
we demonstrate that differences in antibiotic use in different
wards as well as in various hospitals can be explained to a sig-
nificant extent by differences in CMIs of patient populations
admitted to individual hospitals, and thus by differences in
patients’ morbidities.
Data on the correlation of cost indicators and antibiotic use
are scarce in the current literature. To the best of our knowledge,
we present the first study to evaluate such a correlation between
CMI and antibiotic use within a single institution and across
various acute care hospitals. Previously, associations between
CMI and antibiotic use have been studied in long-term care set-
tings.20,21 Mylotte et al. reported the mean facility CMI (using
the so-called Resource Utilization Groups II system) and the
mean facility infection rate to significantly predict mean inci-
dence of antibiotic use in a multilinear model. Furthermore, a
trend towards a significant correlation between CMI and anti-
biotic use was observed by the simple linear regression analy-
sis.20 In another study, these authors found that after controlling
for case mix variation and cost per antibiotic-day, variation in
the infection rate explained most of the variation in incidence of
antibiotic use.21
Our findings have the potential to introduce a novel method
to detect variations in antibiotic prescribing within and between
hospitals. Interpreting quantitative antibiotic use data of various
hospital units that belong to different medical specialties is chal-
lenging due to the lack of possibilities to comprehensively
measure, score and compare morbidities of all individual hospi-
talized patients. However, the identification of high antibiotic
use on a hospital unit level may indicate inappropriate use and
is furthermore crucial in order to detect areas with high antimi-
crobial selection pressure. Other reasons for variations in anti-
biotic prescribing include differences in physician prescribing
preference or varying infection prevalence among hospital
departments or hospitals. At present, however, no straightfor-
ward tools for continuous monitoring of infection prevalence in
hospitals are available. Most hospitals assess the rate of nosoco-
mial infections using periodic prevalence surveys.
Our approach identified hospital units where quantitative anti-
biotic use data cannot be explained by a high CMI. This quanti-
tative signal now necessitates further individualized qualitative
analyses in order to define whether interventions are required to
improve antibiotic use in these units. Furthermore, this principle
can also be applied to compare antibiotic use data between hos-
pitals of a district or on a national level taking into account the
different patient populations across various hospitals. However,
the manner in which cost data are collected and reimbursement
rates are calculated was found to differ among various
countries,19 limiting international comparisons.
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Figure 3. Correlation between antibiotic use and CMI in 13 acute care
hospitals. Correlation between CMI and antibiotic use in 2006 in various
hospitals of the greater Zurich area measured in DDD/100 bed-days (upper
panel) and DDD/100 admissions (lower panel). Weighted linear regression
was used with the size of the dots corresponding to the number of bed-days.
DDD, defined daily doses. ‘Antibiotics’ are all substances of ATC group
‘J01 (Antibacterials for systemic use)’.
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Limitations of our study arise from the shortcomings of
methods to calculate antibiotic use and CMI. Databases for DDD
as well as for DRGs are updated regularly, i.e. definitions and vari-
ables change over time. Consequently, such updates may affect
analyses of CMI and antibiotic use and its correlation, when
different observation periods are compared. Therefore, we repeated
the weighted regression analyses of the University Hospital data
sets for the years 2004 and 2005 (using version 4.1 of the APDRG
Swiss cost weights) and confirmed the significant correlation
between antibiotic use and CMI: in 2004, the correlations between
CMI and DDD/100 bed-days and DDD/100 admissions resulted in
R2 ¼ 0.69 (P, 0.0001) and R2 ¼ 0.53 (P ¼ 0.0004), respectively;
and in 2005, the corresponding results were R2 ¼ 0.72 (P,
0.0001) and R2 ¼ 0.56 (P ¼ 0.0004). Concerning antibiotic use,
the bone marrow transplantation unit is an outlier among the
departments of the university hospital, which might bias the corre-
lation between the different hospitals of the Canton of Zurich.
However, even if the bone marrow transplantation unit was
excluded from the university hospital data, there was still a signifi-
cant correlation between CMI and antibiotic use presented in the
DDD/100 bed-days format [R2 ¼ 0.41, P ¼ 0.0113, slope¼ 45.38
DDD/100 bed-days per CMI (95% CI 12.50–78.26)] as well as in
the DDD/100 admissions format [R2¼ 0.82, P, 0.0001, slope ¼
386.04 DDD/100 admissions per CMI (95% CI 272.77–499.31)]
for the 13 hospitals of the Canton of Zurich.
The ATC/DDD system is a well-accepted and widely used
standard method for measuring antibiotic use, but some limit-
ations have been discussed.4,13,25 For example, calculations of
DDD/100 bed-days and DDD/100 admissions result in discre-
pant antibiotic use data because of the influence of LOS.
Hospitals with a short mean LOS have a low antibiotic use when
measured in DDD/100 admissions as opposed to DDD/100
bed-days, whereas hospitals with a long mean LOS (resulting in
fewer admissions) show a relatively high antibiotic use, if
measured in DDD/100 admissions. LOS is largely influenced by
the type of services offered by a given hospital. If long-term
care facilities or psychiatry wards are part of an acute care hos-
pital, this results in a high mean LOS of these institutions, as
relatively few patients in these units contribute a large number
of bed-days. Nevertheless, we found both variables, DDD/100
bed-days and DDD/100 admissions, to similarly correlate with
CMI. Furthermore, also cost weights are influenced by the
length of hospital stay. Procedures or diseases requiring a long
hospital stay are therefore assigned a higher cost weight irrespec-
tive of the clinical judgement of the severity of a disease. The
costs of implants might further bias case mix calculations. As an
example, implantable cardioverter-defibrillators are more
expensive than pacemakers, whereas the LOS for the implan-
tation or the type of complications arising from the underlying
arrhythmias is similar. As it must be a prerequisite for a bench-
mark to be easily available, we did not make attempts to control
for these biases, e.g. by excluding patients with implants or with
extraordinarily long hospitalizations. Finally, whereas All
Patient-Refined Diagnosis-Related Groups (APR-DRGs) are
used in the USA to compare hospital performance by risk-
adjusting mortality, LOS or inpatient charges,26 it has not yet
been formally evaluated whether APRDRGs indeed provide a
reliable estimate of patient morbidity and mortality.
Other surrogate markers for case mix adjustment of hospital
antibiotic use have been proposed. Lamoth et al.27 observed that
the numbers of blood samples drawn for bacterial culture
enabled accurate identification of periods with a drift in the anti-
biotic consumption in a medical ward. However, the authors
stated that it was uncertain whether these results could be general-
ized to other settings, having found that the principle could not be
applied in a general surgery ward. A few other studies have
approached the problem of comparing different hospitals and
different patient populations by categorizing hospitals according
to their size or type,28,29 whereas others aimed at normalization by
comparing antibiotic use among single medical specialties.29–31
In conclusion, the CMI based on DRGs may be a valuable
tool to facilitate the interpretation of quantitative hospital anti-
biotic use data and to identify areas of concern. Advantages of
this measure are that it can be obtained more easily than labor-
ious morbidity scores, that it is based on nationwide economic
data and that it appears to generate more generalizable data sets
than self-defined case mix measures.15,27,32 Further studies are
needed to determine the role of the various measures that are
proposed for the interpretation of quantitative antibiotic use, to
assess the generalizability of our results and to compare CMI
and DRGs (or similar systems) of different countries with hospi-
tal antibiotic use.
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